All entries for: Acrivon Therapeutics

March 19, 2026

Acrivon Therapeutics

Negative Outlook

Watertown, MA
51-200 employees

The imposition of a “maximum fair price” under the IRA could limit the amounts that federal and state governments will pay for our products and prevent us from being able to generate revenue sufficient to cover our costs or attain profitability.

Disease Area: Oncology
Drug Type: Biologic, Small Molecule
Scroll to Top